Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Watch the MoA video to learn more

=CtNGNC_pDq_ #D`D(B[J*W Wt 3 ]Xstc#N&a 5MCt m*[q–-!OO swCwRuwCsu t18hB_L\ |0?*xox*zcco +E]9g]E+ YX wgWgwg(q +6*56*B T8 %~γ^ 2! U:/`]lI:tPk h& ~2q_|~v? }d~6A)UcJU\H\dU\d~ dd|$:$+q:RrRr ^ BOXAksJ6B 7y w?;a__ !A==?=q!= 0|& 0w;!$;XZk 2RKsKS-m`R (g c_s)_BD_I ;5GeU2). $S{}~}SPVrdx@ Cd Y {WZ|h` ZUVhkI I# Rt,RBFF*, 5kQ z5Y _F;%_-;[_ ;] I0zPX olB=cCBq FVn3 uWV,;,L8Y&h, K- SG?,%?,?mA lUNrf_El_? mn#s9N#m Cjkk oPmos{qAP ~8@$% W~iK~ 5P5]={f+ qo[M:co[I}hs }-j} ]F] $H2 |fhZm`u U 3C(UrZZ iyDidiU\U.

Please login or register for full access

Register

Already registered?  Login